International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Current and Future Treatment of CMV- Robin Avery, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers- Thomas Kakuda, PharmD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph Custodio

Slideset

HIV

Viral Hepatitis and Liver Disease

O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia Majeed

Slideset

HIV

Viral Hepatitis and Liver Disease

O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCP

Slideset

HIV

Viral Hepatitis and Liver Disease

Clinical Aspects of Pediatric Treatment- Tim Cressey, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCP

Slideset

HIV

Viral Hepatitis and Liver Disease

O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline Bollen

Slideset

HIV

Viral Hepatitis and Liver Disease

O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis- Kimberly Adkison, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.- Sandrine Lefeuvre

Slideset

HIV

Viral Hepatitis and Liver Disease

HBV therapy & Approaches to Cure- Jordan Feld, MD, MPH

Slideset

HIV

Viral Hepatitis and Liver Disease

FDA perspective- Kellie Reynolds, PharmD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp- Brian Kirby, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015- Tyler Shugg, PharmD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence- Nathan Hanan

Slideset

HIV

Viral Hepatitis and Liver Disease

O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration- Steven Sanche

Slideset

HIV

Viral Hepatitis and Liver Disease

O_15: Identification of long-acting NRTI candidates through in silico modelling- Marco Siccardi, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects- Mark Johnson, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilater- Matthew Kosloski

Slideset

HIV

Viral Hepatitis and Liver Disease

O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme- Omar Elsherif

Slideset

HIV

Viral Hepatitis and Liver Disease

O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens- Kimberly Garrison

Slideset

HIV

Viral Hepatitis and Liver Disease

O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin- Su-Young Choi, PharmD, PhD

Slideset

HIV

Viral Hepatitis and Liver Disease

Pro Standpoint- Nancy Reau, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Con Standpoint- Jürgen Rockstroh, MD

Slideset

HIV

Viral Hepatitis and Liver Disease

Janssen: Influenza- Thomas Kakuda, PharmD

Slideset

HIV

Viral Hepatitis and Liver Disease

Gilead: RSV - Erik Mogalian

Slideset

HIV

Viral Hepatitis and Liver Disease

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017

Current and Future Treatment of CMV- Robin Avery, MD

O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers- Thomas Kakuda, PharmD

O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhD

O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph Custodio

O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia Majeed

O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhD

O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhD

Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCP

Clinical Aspects of Pediatric Treatment- Tim Cressey, PhD

O_8: Relationship between dolutegravir plasma exposure, quality of sleep and its functional outcome in patients living with HIV over the age of 60 years.- Marta Boffito, MD, PhD, FRCP

O_7: A Comparison of the Pharmacokinetics of Dolutegravir during Pregnancy and Postpartum- Dr Pauline Bollen

O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis- Kimberly Adkison, PhD

O_11: HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.- Sandrine Lefeuvre

HBV therapy & Approaches to Cure- Jordan Feld, MD, MPH

FDA perspective- Kellie Reynolds, PharmD

O_13: CYP3A induction data can predict other P450 and drug transporter DDI liability: An example of carbamazepine and rifabutin with sofosbuvir and P-gp- Brian Kirby, MD

O_12: Examining the Basis of Drug-Drug Interaction Labeling Recommendations for Antiviral Approvals from 1998 to 2015- Tyler Shugg, PharmD, PhD

DDI’s in Aging HIV infected Patients- Alice Pau, PharmD

Long Acting Antivirals: Advanced drug delivery- Mark Milad, PharmD

DDI’s in Aging HCV infected Patients- Elise Smolders, MSc

O_14: Pharmacokinetics of Co-encapsulated Truvada® with Ingestible Sensor to Assess Adherence- Nathan Hanan

O_16: A mathematical model that predicts virological failure and elucidates the impact of lymph node drug penetration- Steven Sanche

O_15: Identification of long-acting NRTI candidates through in silico modelling- Marco Siccardi, PhD

O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects- Mark Johnson, MD

O_18: Drug-drug interactions of Glecaprevir and Pibrentasvir with Pravastatin, Rosuvastatin, or Dabigatran etexilater- Matthew Kosloski

O_19: Influences on Pharmacokinetics of ledipasvir, sofosbuvir and GS-331007 in patients with decompensated cirrhosis – results from the UK Expanded Access programme- Omar Elsherif

O_20: Evaluation of Drug-Drug Interactions between Sofosbuvir/Velpatasvir/Voxilaprevir and Boosted or Unboosted HIV Antiretroviral Regimens- Kimberly Garrison

O_21: The Potential Role of PK-Based Drug Interactions in FAERS-Reported Rhabdomyolysis Cases in Patients Receiving a DAA Regimen and a Statin- Su-Young Choi, PharmD, PhD

Pro Standpoint- Nancy Reau, MD

Con Standpoint- Jürgen Rockstroh, MD

Janssen: Influenza- Thomas Kakuda, PharmD

Gilead: RSV - Erik Mogalian

Merck: CMV - Cyrus Badshah, MD, PhD